Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.39 |
| ▸ | KLK7 | P49862 | 6/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929841 | 1.00 | FPR2 (0.39) | FPR2KLK7RORCPOLBKLK5 | |
| SCHEMBL12241769 | 0.89 | TP53 (0.45) | KLK7POLBKLK5KMT2ATP53 | |
| SCHEMBL26439216 | 0.88 | VEGFA (0.41) | KLK7KLK5KMT2ATP53 | |
| SCHEMBL26707683 | 0.88 | VEGFA (0.41) | KLK7KLK5KMT2ATP53 | |
| SCHEMBL22154819 | 0.88 | KLK7 (0.39) | KLK7POLBKLK5KMT2ATP53 | |
| SCHEMBL15383781 | 0.88 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL3728443 | 0.88 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL19419776 | 0.88 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598705 | 0.86 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL1594928 | 0.86 | P2RX7 (0.43) | KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150166469-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-18 | — | — | US | disclosed |
| US-8901169-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130330366-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-12-12 | — | — | US | disclosed |
| US-8586536-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1594/4885KLK7 241/4885RORC 4543/4885 |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1470/4885KLK7 225/4885RORC 4528/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1594/4885KLK7 241/4885RORC 4543/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | FPR2 2255/4885KLK7 262/4885RORC 2954/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | FPR2 1594/4885KLK7 241/4885RORC 4543/4885 |
| US-20130330366-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 2255/4885KLK7 262/4885RORC 2954/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | FPR2 1354/4885KLK7 302/4885RORC 4649/4885 |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1354/4885KLK7 302/4885RORC 4649/4885 |
| US-20150166469-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1470/4885KLK7 225/4885RORC 4528/4885 |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | FPR2 86/4885KLK7 1061/4885RORC 2251/4885 |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | FPR2 2159/4885KLK7 306/4885RORC 4467/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1354/4885KLK7 302/4885RORC 4649/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1362/4885KLK7 304/4885RORC 4621/4885 |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FPR2 1594/4885KLK7 241/4885RORC 4543/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | FPR2 1354/4885KLK7 302/4885RORC 4649/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | FPR2 1594/4885KLK7 241/4885RORC 4543/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | FPR2 87/4885KLK7 1065/4885RORC 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.